Clinical Trials
30 trialsPhase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
M.D. Anderson Cancer Center
Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers
National Institutes of Health Clinical Center (CC)
Anti-CRLF2-R/TSLPR Chimeric Antigen Receptor T Cells (TSLPR-CART) in Participants With Recurrent or Refractory CRLF2-R/TSLPR-Overexpressing B-Cell Acute Lymphoblastic Leukemia (B-ALL)
National Institutes of Health Clinical Center (CC)
A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL)
Wake Forest University Health Sciences
ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
University of California, San Francisco
Pirtobrutinib Maintenance After CAR-T Therapy in Relapsed or Refractory B-Cell Lymphoma
Sun Yat-sen University
CAR-T Treatment in Pediatric and Adult Acute Lymphoblastic Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto
PACIFIC
French Innovative Leukemia Organisation
Digitalized Exercise Fit Tool Intervention for Adolescents With Blood Cancer
The Hong Kong Polytechnic University
REFRACT-LyMA
Nantes University Hospital
ASCLEPIO
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma
Sun Yat-sen University
FXS0683-001
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
U96-CAR-T-Cells For R/R B-ALL
The First Affiliated Hospital of Soochow University
Study of Sugemalimab (or Placebo) Plus PGemOx Regimen in Participants With Extranodal NK/T-Cell Lymphoma
CStone Pharmaceuticals
A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL
GlaxoSmithKline
FLASH Pilot Phase 1 Safety Study
Dartmouth-Hitchcock Medical Center
Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma
The First Affiliated Hospital of Soochow University
A Phase 2 Study of Lacutoclax (LP-108) in Patients With Relapsed/Refractory CLL/SLL
Guangzhou Lupeng Pharmaceutical Company LTD.
A Phase Ib/II Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
Guangzhou Lupeng Pharmaceutical Company LTD.
Real World Asparaginase Therapy Toxicity
St. Jude Children's Research Hospital
Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas
Abramson Cancer Center at Penn Medicine
HEMO-CONNECT
Centre Hospitalier de la côte Basque
Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma
Sun Yat-sen University
A Phase I Study of JL19001 Injection Alone or in Combination With Standard Therapy in Patients With Advanced Solid Tumors or Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Jecho Biopharmaceuticals Co., Ltd.
Phase 2 Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL
M.D. Anderson Cancer Center
Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Novartis
FC-BALANCE
Swiss Cancer Institute
Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
City of Hope Medical Center
Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma
University of California, San Francisco